HighGravityDataBioMarin Pharmaceutical — Aug 4, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000088
Showing in the filing
VOXZOGO contribution to full-year 2025 Total Revenues
“$900 million to $935 million”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 9
VOXZOGO country access target for FY2027
“more than 60 countries”
VOXZOGO revenue for FY2025
“expected to drive higher VOXZOGO revenue in the second half of 2025 compared to the first half of 2025, and weighted to Q4”
Total Enzyme Therapies revenues for FY2025
“expected to remain robust”
Operating expenses for FY2025
“expected to increase in the second half of 2025 vs. the first half of 2025”
Total Revenues for FY2025
“$3,125 to $3,200”
Non-GAAP Operating Margin % for FY2025
“33% to 34%”
Non-GAAP Diluted EPS for FY2025
“$4.40 to $4.55”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $935 million”
Non-GAAP Diluted EPS assumed Weighted-Averag… for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
2025 Full-Year Financial Guidance (in millions, except % and EPS amounts) Item Provided on May 1, 2025 Updated August 4, 2025 Total Revenues (1) $3,100 to $3,200 $3,125 to $3,200 Non-GAAP Operating Margin % (2)(4) 32% to 33% 33% to 34% Non-GAAP Diluted EPS (2)(3)(4) $4.20 to $4.40 $4.40 to $4.55 (1) VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $935 million. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. (4) Excludes the estimated impact of acquired IPR&D charges from BioMarin’s acquisition of Inozyme, which was completed on July 1, 2025. Accounting for the Inozyme transaction will be finalized and included in the company’s third quarter financial results, which are subject to BioMarin’s financial statement closing procedures. The company expects to provide an update on full-year 2025 guidance items, including impact of the acquired IPR&D charges, in its third quarter 2025 earnings update. While acquired IPR&D charges may be incurred upon execution of acquisitions, collaborations, licensing agreements, and other business development transactions, BioMarin does not forecast acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period. BioMarin will host a conference call and webcast to discuss second quarter 2025 financial results today, Monday,
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.